Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Henry

Showing results (121-130 of 155) with videos related to

Pageof 16
Sort By:
Diabetes, Obesity & Metabolism|February 14, 2018
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trialKausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland, et al.
Cardiovascular Diabetology|May 27, 2017
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular riskDirk Müller-Wieland, Lawrence A Leiter, Bertrand Cariou, et al.
Metabolism: Clinical and Experimental|October 8, 2017
Circulating ApoJ is closely associated with insulin resistance in human subjectsJi A Seo, Min-Cheol Kang, Theodore P Ciaraldi, et al.
American Heart Journal|September 11, 2013
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialA Michael Lincoff, Jean-Claude Tardif, Bruce Neal, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2012
Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinaseZhao He, Helen H Zhu, Timothy J Bauler, et al.
Journal of the American College of Cardiology|September 1, 2004
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitusMeenakshi A Bhalla, Audrey Chiang, Victoria A Epshteyn, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 16, 2016
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSISYehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, et al.
BMC Endocrine Disorders|July 31, 2009
Actos Now for the prevention of diabetes (ACT NOW) studyRalph A Defronzo, Maryann Banerji, George A Bray, et al.
Nature Reviews. Disease Primers|May 19, 2016
Type 2 diabetes mellitusRalph A DeFronzo, Ele Ferrannini, Leif Groop, et al.
Food & Function|November 25, 2017
A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpointsAldo Moreno-Ulloa, Nayelli Nájera-García, Marcela Hernández, et al.
Pageof 16

Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
Diabetes, Obesity & Metabolism|February 14, 2018
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trialKausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland, et al.
Cardiovascular Diabetology|May 27, 2017
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular riskDirk Müller-Wieland, Lawrence A Leiter, Bertrand Cariou, et al.
Metabolism: Clinical and Experimental|October 8, 2017
Circulating ApoJ is closely associated with insulin resistance in human subjectsJi A Seo, Min-Cheol Kang, Theodore P Ciaraldi, et al.
American Heart Journal|September 11, 2013
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialA Michael Lincoff, Jean-Claude Tardif, Bruce Neal, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2012
Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinaseZhao He, Helen H Zhu, Timothy J Bauler, et al.
Journal of the American College of Cardiology|September 1, 2004
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitusMeenakshi A Bhalla, Audrey Chiang, Victoria A Epshteyn, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 16, 2016
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSISYehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, et al.
BMC Endocrine Disorders|July 31, 2009
Actos Now for the prevention of diabetes (ACT NOW) studyRalph A Defronzo, Maryann Banerji, George A Bray, et al.
Nature Reviews. Disease Primers|May 19, 2016
Type 2 diabetes mellitusRalph A DeFronzo, Ele Ferrannini, Leif Groop, et al.
Food & Function|November 25, 2017
A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpointsAldo Moreno-Ulloa, Nayelli Nájera-García, Marcela Hernández, et al.
Pageof 16